Decrease in Pharma Business Drives Response Genetics' Q3 Revenues Down 10 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Driven by a downswing in revenues from its pharmaceutical clients, Response Genetics today said that third-quarter revenues dipped 10 percent year over year to $5.1 million.

Revenues for the three months ended Sept. 30 compare to $5.6 million for the third quarter a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.